Showing results (1011-1020 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|December 14, 2011
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignanciesGlen J Weiss, Manuel Hidalgo, Mitesh J Borad, et al.
Investigational New Drugs|December 14, 2011
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG studyWarren P Mason, Mary Macneil, Petr Kavan, et al.
Investigational New Drugs|October 11, 2011
A new synthetic HDAC inhibitor, MHY218, induces apoptosis or autophagy-related cell death in tamoxifen-resistant MCF-7 breast cancer cellsJi Hye Park, Mee Young Ahn, Tae Hyung Kim, et al.
Investigational New Drugs|May 28, 2009
The activity of mTOR inhibitor RAD001 (everolimus) in nasopharyngeal carcinoma and cisplatin-resistant cell linesBrigette B Y Ma, Vivian W Y Lui, Edwin P Hui, et al.
Investigational New Drugs|June 12, 2009
Tea polyphenols inhibit cyclooxygenase-2 expression and block activation of nuclear factor-kappa B and Akt in diethylnitrosoamine induced lung tumors in Swiss micePreeti Roy, Nidhi Nigam, Madhulika Singh, et al.
Investigational New Drugs|February 25, 2009
A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503Anne M Traynor, Ju-Whei Lee, Gerald K Bayer, et al.
Investigational New Drugs|June 24, 2009
Yttrium-90-ibritumomab tiuxetan in combination with intravenous busulfan, cyclophosphamide, and etoposide followed by autologous stem cell transplantation in patients with relapsed or refractory B-cell non-Hodgkin's lymphomaByung Woog Kang, Won Seog Kim, Chul Kim, et al.
Investigational New Drugs|January 17, 2012
Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapyCéline Clémenson, Cyrus Chargari, Laurent Désiré, et al.
Investigational New Drugs|February 15, 2012
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumorsPamela L Kunz, Aiwu R He, A Dimitrios Colevas, et al.
Investigational New Drugs|February 24, 2012
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expressionZarina J D'Costa, Cheng-Mee Leong, Justin Shields, et al.
Pageof 372